Publications by authors named "Keneng Chen"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

153

Total Likes

216

Extended Reach

782,060

Social Features

87
E
Establishment of a Chinese library of patient-derived xenografts from gastrointestinal cancers.
Ying Liu, Wei He, Qi Wu, Jia-Fu Ji, Lin Shen, Ke-Neng Chen, Huan-Yu Chen

BMC Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 2025 American Association for Thoracic Surgery (AATS) expert consensus document: Surgical management of esophageal and gastroesophageal junction cancer.
Daniela Molena, Marisa Sewell, Steve B Maron, Wayne Hofstetter, Stephanie Worrell, Ke-Neng Chen

J Thorac Cardiovasc Surg· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
Patrick M Forde, Jonathan D Spicer, Mariano Provencio, Tetsuya Mitsudomi, Mark M Awad, Ke-Neng Chen

N Engl J Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of nutritional support during neoadjuvant therapy on perioperative outcome in esophageal cancer: a real-world cohort study.
Yongbo Yang, Yan He, Wan Wei, Yaya Wu, Hong Chen, Ke-Neng Chen

J Thorac Dis· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathologic complete response after neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Endoscopic characteristics and implications.
Peng Yuan, Zongchao Liu, Liang Dai, Yan Yan, Yaya Wu, Keneng Chen

Endosc Int Open· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) monotherapy versus combined EGFR-TKI and chemotherapy in resectable EGFR-mutant non-small cell lung cancer: a real-world multicenter retrospective study.
Mengying Fan, Zerui Zhao, Wanpu Yan, Hao Fu, Shijie Huang, Ke-Neng Chen

Transl Lung Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Application Value of Neoadjuvant Targeted Therapy in Patients with EGFR-mutant 
Resectable Lung Adenocarcinoma].
Shijie Huang, Mengying Fan, Kaiming Peng, Wanpu Yan, Boyang Chen, Keneng Chen

Zhongguo Fei Ai Za Zhi· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant immunotherapy does not improve survival in non-small cell lung cancer with major/complete pathologic response after induction immunotherapy.
Ze-Rui Zhao, Wan-Pu Yan, Xiang-Yang Yu, Jing-Bo Zhang, Yi-Fan Fang, Ke-Neng Chen

J Thorac Cardiovasc Surg· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing response in endoscopy images of esophageal cancer treated with total neoadjuvant therapy via hybrid-architecture ensemble deep learning.
Peng Yuan, Meichen Liu, Hangzhou He, Liang Dai, Ya-Ya Wu, Ke-Neng Chen

Front Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.
Mark M Awad, Patrick M Forde, Nicolas Girard, Jonathan Spicer, Changli Wang, Ke-Neng Chen

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility and safety of perioperative entrectinib in a patient with ROS1-positive locally advanced NSCLC: A case report.
Mengying Fan, Wanpu Yan, Minglei Zhuo, Rong Yu, Liping Qi, Ke-Neng Chen

Lung Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognosis and relapse patterns in patients with non-small cell lung cancer with pathologic complete response after neoadjuvant immunochemotherapy.
Yifan Fang, Wanpu Yan, Ze-Rui Zhao, Long Jiang, Xiangyang Yu, Ke-Neng Chen

J Thorac Dis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined Chemotherapy and Immunotherapy Induction for Screening of Patients with Cervical Esophageal Carcinoma for Subsequent Local Treatment: A New Treatment Paradigm.
Liang Dai, Ya-Ya Wu, Yan Sun, Rong Yu, Wan-Pu Yan, Hong Cheng, Ke-Neng Chen

Ann Surg Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Combined Chemotherapy and Immunotherapy Induction for Screening of Patients with Cervical Esophageal Carcinoma for Subsequent Local Treatment: A New Treatment Paradigm.
Liang Dai, Ya-Ya Wu, Yan Sun, Rong Yu, Wan-Pu Yan, Hong Cheng, Ke-Neng Chen

Ann Surg Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASO Author Reflections: On the Sources of Dispute in the Treatment of Cervical Esophageal Cancer.
Ke-Neng Chen

Ann Surg Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jonathan D Spicer, Marina C Garassino, Heather Wakelee, Moishe Liberman, Terufumi Kato, Ke-Neng Chen

Lancet· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Survival and Recurrence Patterns in Locally Advanced Esophageal Squamous Cell Carcinoma Patients with Pathologic Complete Response After Neoadjuvant Chemotherapy Followed by Surgery.
Ya-Ya Wu, Liang Dai, Yong-Bo Yang, Wan-Pu Yan, Hong Cheng, Ke-Neng Chen

Ann Surg Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in the recent three decades and survey on the current status of surgical treatment for esophageal cancer in China.
Yong Li, Wei-Xin Liu, Ling Qi, Yin Li, Jun-Feng Liu, Ke-Neng Chen

Thorac Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASO Author Reflections: The Challenging Journey from cCR to pCR After Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma.
Ke-Neng Chen

Ann Surg Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
China Anti-Cancer Association Guidelines for the diagnosis, treatment, and follow-up of thymic epithelial tumors (2023).
Wentao Fang, Zhentao Yu, Chun Chen, Gang Chen, Keneng Chen

Mediastinum· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.
Shun Lu, Wei Zhang, Lin Wu, Wenxiang Wang, Peng Zhang, Qixun Chen, Yuping Chen, Keneng Chen, Jun Chen, Gang Chen

JAMA· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Ke-Neng Chen

N Engl J Med· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC.
Yong Li, Aiping Zhou, Shuoyan Liu, Ming He, Keneng Chen, Haiquan Chen

BMC Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial.
Wen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, Chun Chen, Chun-Dong Gu, Ying Cheng, Ming-Wei Chen

Signal Transduct Target Ther· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis